Pfizer, Moderna and Gilead see reputation boost To view this email as a web page,
click here Kodak's $765 million manufacturing loan on the rocks as red flags multiply CVS, Salesforce team up to unite return-to-work platforms Pfizer, Moderna and Gilead reputations climb on COVID-19 vaccine and treatment news, according to Harris Poll Biopharma roundup: Slow enrollment slims Moderna's odds for a 2020 shot approval; Experts won't be fooled again on Inovio vaccine Healthcare roundup: U.S. hits 5M confirmed COVID-19 cases AbbVie infectious disease exec jumps ship to COVID antiviral biotech Kaiser Permanente reports $4.5B in Q2 net income as COVID-19 drives down operating costs PPD squeezes out a revenue growth despite COVID-19 disruption GigaGen’s polyclonal antibody against COVID-19 outperforms plasma in lab tests Featured Story | By Kyle Blankenship Eastman Kodak's unlikely deal with the federal government to dive into drug manufacturing has raised eyebrows, not only for the size of the loan itself but Kodak's lack of experience—and some executive stock option grants that preceded the announcement. Now, with investigations mounting, the U.S. is pumping the brakes. read more |
| |
|---|
|
Top Stories By Paige Minemyer CVS Health and Salesforce are partnering to bring together their return-to-work platforms. read more By Beth Snyder Bulik The latest Harris Poll numbers on pharma reputations and COVID-19 vaccines and treatments finds that drugmakers in the news reaped hefty boosts to their image. The early August data show Pfizer, Gilead Sciences and Moderna trending positively with consumers who'd seen their news about treatments and vaccines. read more By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner Health experts think slow enrollment could push Moderna's phase 3 results into next year. Analysts cut through the hype for Inovio's COVID-19 shot. Russia took heat for plans to inoculate the public with an unapproved vaccine. Drugmakers doing COVID-19 work saw their public perception rise. Plus, PPD's revenue rose in Q2 on COVID-19 efforts. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Ben Adams AbbVie and Roche alum Janet Hammond, M.D., Ph.D., Sc.M., F.C.P. has nabbed the chief development officer role at infectious disease biotech Atea Pharmaceuticals. read more By Paige Minemyer Kaiser Permanente earned $4.5 billion in net income in the second quarter after a "challenging" Q1 as deferred procedures under the pandemic drove down operating costs. read more By Ben Adams Contract Research Organization PPD has seen its revenue nudge up in the second quarter as it navigates trial disruption while helping run one of the world’s most closely watched vaccine trials. read more By Arlene Weintraub San Francisco startup GigaGen team took plasma from 50 COVID-19 survivors in Louisiana and used it to quickly create a polyclonal antibody to fight the disease. The antibody was 100 times more protective against the disease than convalescent plasma in lab tests and is headed to clinical trials early next year. read more |
|
